Rani Announces Pricing Of $20 Mln Direct Offering At $1.07 Per Share; Stock Down

Rani Therapeutics announced pricing for a $20 million registered direct offering. The financing is a routine capital raise for the clinical-stage biotherapeutics company and may modestly affect liquidity and dilution, but the article provides no additional operational or clinical updates.

Analysis

Rani Therapeutics announced pricing for a $20 million registered direct offering. The financing is a routine capital raise for the clinical-stage biotherapeutics company and may modestly affect liquidity and dilution, but the article provides no additional operational or clinical updates.